In the last 90 days, Grace Therapeutics, Inc. insiders filed 11 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Grace Therapeutics, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Grace Therapeutics, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Nov 12, 2026
8-KCurrent report
2.02Item 2.02: Results of operations and financial condition (earnings release)9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
2.02Item 2.02: Results of operations and financial condition (earnings release)8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.02Item 3.02: Unregistered sale of equity securities8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement3.03Item 3.03: Material modification to the rights of security holders5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.07Item 5.07: Results of a shareholder vote9.01Item 9.01: Financial statements and exhibits
